Table 2.
Antianginal treatments at baseline
| Medications | Group 1 n = 75 (100%) |
Group 2 n = 243 (100%) |
Group 3 n = 242 (100%) |
Group 4 n = 181 (100%) |
|---|---|---|---|---|
| Monotherapy | 47 (62.67) | 131 (53.91) | 111 (45.87) | 88 (48.62) |
| BB | 45 (60.00) | 122 (50.21) | 98 (40.50) | 82 (45.30) |
| CCB | 2 (2.67) | 8 (3.29) | 9 (3.72) | 2 (1.10) |
| LAN | 0 (0.00) | 1 (0.41) | 4 (1.65) | 4 (2.21) |
| Two-drug combination | 21 (28.00) | 93 (38.27) | 102 (42.15) | 73 (40.33) |
| BB + CCB | 13 (17.33) | 61 (25.10) | 59 (24.38) | 41 (22.65) |
| BB + LAN | 8 (10.67) | 32 (13.17) | 41 (16.94) | 30 (16.57) |
| CCB + LAN | 0 (0.00) | 0 (0.00) | 2 (0.83) | 2 (1.10) |
| Three-drug combination | 6 (8.00) | 16 (6.58) | 22 (9.09) | 14 (7.73) |
| BB + CCB + LAN | 6 (8.00) | 16 (6.58) | 22 (9.09) | 14 (7.73) |
| Neither BB, CCB nor LAN | 1 (1.33) | 3 (1.23) | 7 (2.89) | 6 (3.31) |
Data are presented as number of patients with percentage in parentheses
BB beta-blockers, CCB calcium channel blockers, LAN long-acting nitrates